Durham, N.C. – January 24, 2018 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the post approval study to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease. The first case was performed by R. Lee Jobe, M.D., …
Tryton Medical announces new CEO and president
Durham, N.C. – Jan. 3, 2018 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has appointed Carl J. St. Bernard as president and chief executive officer. St. Bernard has a long track record growing new and established businesses in pharmaceuticals, consumer health products, medical devices and diagnostic markets. …
Innovative Tryton Side Branch Stent Recognized with the Premier Technology Breakthrough Award
DUBLIN, Ohio, September 19, 2017 — Cardinal Health and Tryton Medical Inc. today announced that the Tryton coronary Side Branch Stent was recognized by Premier Inc., a leading healthcare improvement company, with the prestigious Technology Breakthrough Award. Premier’s Technology Breakthrough Award is granted to cutting-edge products that significantly advance healthcare in terms of safety, clinical outcomes and/or operational efficiency. The …
Tryton Medical Announces First U.S. Commercial Case with Tryton Side Branch Stent
Patient with coronary bifurcation lesion involving large side branch treated with first dedicated bifurcation stent to receive regulatory approval in the U.S. “Dr. Leon and the cath lab team at Columbia University Medical Center played an integral role investigating the Tryton Side Branch Stent through extensive clinical research leading to the recent FDA approval” DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the …
Tryton Medical Receives FDA Approval for Tryton Side Branch Stent to Treat Significant Coronary Bifurcation Lesions
Tryton stent is the first dedicated bifurcation device to receive regulatory approval in the U.S. Cordis to be exclusive U.S. distributor of the Tryton stent. “A predictable bifurcation solution helps alleviate some of the stress in these procedures by limiting variability and reducing the need for bailout stenting. This important FDA decision could have a profound impact on treatment protocols …
Tryton Medical Enters Into Strategic Agreement with Cardinal Health
Long-term collaboration for U.S. distribution of Tryton Side Branch Stent pending regulatory approval. “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions.” DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies …
Tryton Medical Announces Clinical Symposium on Treatment of Complex Bifurcation Lesions at TCT 2016
Faculty of leading global interventional cardiologists to review results from safety and efficacy studies of Tryton Side Branch Stent “This symposium presents an exciting opportunity to learn about treating bifurcation lesions from leading interventionists from around the world” DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that the company is …
Outcomes from Tryton Medical Pivotal Confirmatory Study Published in JACC Cardiovascular Interventions
Study met primary endpoint, results confirm safety profile for treatment of coronary bifurcation lesions involving large side branches “Bifurcation lesions are a common challenge for interventional cardiologists, present in 20%-30% of coronary lesions treated with percutaneous coronary intervention” DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results from the …
Tryton Medical Files Pre-Market Approval Application with US FDA for Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Application is supported by results from the pivotal Tryton Confirmatory Study in the treatment of significant coronary bifurcation lesions. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug …
Tryton Meets Primary Endpoint in Pivotal Confirmatory Study of Tryton Side Branch Stent in Treatment of Coronary Bifurcation Lesions
Dateline City: DURHAM, N.C. Positive results presented at Transcatheter Cardiovascular Therapeutics symposium support planned PMA submission. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced results from the pivotal Tryton Confirmatory Study confirming the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions …